Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Up to $12.33

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) gapped up prior to trading on Friday . The stock had previously closed at $12.33, but opened at $13.07. Y-mAbs Therapeutics shares last traded at $12.88, with a volume of 11,538 shares traded.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on YMAB shares. BMO Capital Markets raised their target price on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the company an “outperform” rating in a research report on Monday, March 4th. Truist Financial started coverage on Y-mAbs Therapeutics in a report on Friday. They set a “buy” rating and a $21.00 price target for the company. Canaccord Genuity Group increased their price objective on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Finally, HC Wainwright upped their price objective on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Monday, May 13th. Two equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $17.86.

Y-mAbs Therapeutics Stock Up 2.4 %

The firm has a 50 day moving average of $13.13 and a 200 day moving average of $12.74. The firm has a market cap of $554.20 million, a price-to-earnings ratio of -25.16 and a beta of 0.69.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Tuesday, May 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). The company had revenue of $19.93 million for the quarter, compared to analyst estimates of $22.06 million. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. Equities analysts expect that Y-mAbs Therapeutics, Inc. will post -0.45 EPS for the current year.

Insider Activity

In other news, insider Thomas Gad sold 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $12.00, for a total transaction of $300,000.00. Following the transaction, the insider now directly owns 240,032 shares of the company’s stock, valued at $2,880,384. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Thomas Gad sold 25,000 shares of the company’s stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $12.00, for a total value of $300,000.00. Following the completion of the sale, the insider now owns 240,032 shares in the company, valued at approximately $2,880,384. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Bo Kruse sold 31,371 shares of Y-mAbs Therapeutics stock in a transaction on Friday, May 31st. The stock was sold at an average price of $12.07, for a total value of $378,647.97. Following the sale, the chief financial officer now owns 210,877 shares in the company, valued at $2,545,285.39. The disclosure for this sale can be found here. Insiders sold a total of 99,444 shares of company stock worth $1,203,925 in the last three months. Company insiders own 21.50% of the company’s stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

A number of hedge funds have recently modified their holdings of YMAB. GSA Capital Partners LLP increased its position in Y-mAbs Therapeutics by 208.3% in the third quarter. GSA Capital Partners LLP now owns 137,299 shares of the company’s stock worth $748,000 after buying an additional 92,765 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new position in shares of Y-mAbs Therapeutics during the 4th quarter worth $562,000. Trexquant Investment LP increased its holdings in Y-mAbs Therapeutics by 417.5% in the 3rd quarter. Trexquant Investment LP now owns 76,585 shares of the company’s stock worth $417,000 after acquiring an additional 61,785 shares during the last quarter. Los Angeles Capital Management LLC raised its stake in Y-mAbs Therapeutics by 17.3% in the 4th quarter. Los Angeles Capital Management LLC now owns 356,530 shares of the company’s stock valued at $2,432,000 after acquiring an additional 52,610 shares during the period. Finally, Sapient Capital LLC purchased a new stake in Y-mAbs Therapeutics during the fourth quarter valued at about $298,000. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.